{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:49:20Z","timestamp":1791906560411,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00482-011-1132-2","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T17:27:00Z","timestamp":1330104420000},"page":"16-26","source":"Crossref","is-referenced-by-count":18,"title":["Unerw\u00fcnschte Nebenwirkungen von Tapentadol im Vergleich zu Oxycodon","Undesired side effects of tapentadol in comparison to oxycodone"],"prefix":"10.1007","volume":"26","author":[{"given":"M.","family":"Merker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kranke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,26]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","unstructured":"Afilalo M, Etropolski MS, Kuperwasser B et\u00a0al (2010) Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase\u00a0III study. Clin Drug Investig 30:489\u2013505","journal-title":"Clin Drug Investig"},{"key":"1132_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/11319200-000000000-00000","volume":"33","author":"Brunton","year":"2010","unstructured":"Brunton S, Wang F, Edwards SB et\u00a0al (2010) Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 33:393\u2013407","journal-title":"Drug Saf"},{"key":"1132_CR3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","volume":"11","author":"Buynak","year":"2010","unstructured":"Buynak R, Shapiro DY, Okamoto A et\u00a0al (2010) Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase\u00a0III study. Expert Opin Pharmacother 11:1787\u20131804","journal-title":"Expert Opin Pharmacother"},{"key":"1132_CR4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","volume":"25","author":"Bymaster","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et\u00a0al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871\u2013880","journal-title":"Neuropsychopharmacology"},{"key":"1132_CR5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1185\/03007990902952825","volume":"25","author":"Daniels","year":"2009","unstructured":"Daniels S, Casson E, Stegmann JU et\u00a0al (2009) A randomized, double-blind, placebo-controlled phase\u00a03 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 25:1551\u20131561","journal-title":"Curr Med Res Opin"},{"key":"1132_CR6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1185\/03007990902728183","volume":"25","author":"Daniels","year":"2009","unstructured":"Daniels SE, Upmalis D, Okamoto A et\u00a0al (2009) A randomized, double-blind, phase\u00a0III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 25:765\u2013776","journal-title":"Curr Med Res Opin"},{"key":"1132_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.36076\/ppj.2010\/13\/61","volume":"13","author":"Etropolski","year":"2010","unstructured":"Etropolski MS, Okamoto A, Shapiro DY et\u00a0al (2010) Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician 13:61\u201370","journal-title":"Pain Physician"},{"key":"1132_CR8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2165\/11204470-000000000-00000","volume":"70","author":"Frampton","year":"2010","unstructured":"Frampton JE (2010) Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70:1719\u20131743","journal-title":"Drugs"},{"key":"1132_CR9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2006.11.003","volume":"55","author":"Garcia-Quetglas","year":"2007","unstructured":"Garcia-Quetglas E, Azanza JR, Sadaba B et\u00a0al (2007) Pharmacokinetics of tramadol enantiomers and their respective phase\u00a0I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 55:122\u2013130","journal-title":"Pharmacol Res"},{"key":"1132_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","volume":"95","author":"Gillman","year":"2005","unstructured":"Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95:434\u2013441","journal-title":"Br J Anaesth"},{"key":"1132_CR11","first-page":"CD002024","volume":"Rev","author":"Gowing","year":"2009","unstructured":"Gowing L, Farrell M, Ali R et\u00a0al (2009) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev:CD002024","journal-title":"Cochrane Database Syst"},{"key":"1132_CR12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1185\/03007990902816970","volume":"25","author":"Hale","year":"2009","unstructured":"Hale M, Upmalis D, Okamoto A et\u00a0al (2009) Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90\u00a0days: a randomized, double-blind study. Curr Med Res Opin 25:1095\u20131104","journal-title":"Curr Med Res Opin"},{"key":"1132_CR13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clinthera.2009.02.009","volume":"31","author":"Hartrick","year":"2009","unstructured":"Hartrick C, Van Hove I, Stegmann JU et\u00a0al (2009) Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase\u00a0III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 31:260\u2013271","journal-title":"Clin Ther"},{"key":"1132_CR14","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1517\/14656560903313734","volume":"10","author":"Hartrick","year":"2009","unstructured":"Hartrick CT (2009) Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 10:2687\u20132696","journal-title":"Expert Opin Pharmacother"},{"key":"1132_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et\u00a0al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"1132_CR16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","volume":"14","author":"Kress","year":"2010","unstructured":"Kress HG (2010) Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14:781\u2013783","journal-title":"Eur J Pain"},{"key":"1132_CR17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","volume":"27","author":"Lange","year":"2010","unstructured":"Lange B, Kuperwasser B, Okamoto A et\u00a0al (2010) Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 27:381\u2013399","journal-title":"Adv Ther"},{"key":"1132_CR18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/00000542-200506000-00027","volume":"102","author":"Marret","year":"2005","unstructured":"Marret E, Kurdi O, Zufferey P et\u00a0al (2005) Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 102:1249\u20131260","journal-title":"Anesthesiology"},{"key":"1132_CR19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(02)00009-6","volume":"66","author":"Millan","year":"2002","unstructured":"Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355\u2013474","journal-title":"Prog Neurobiol"},{"key":"1132_CR20","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J et\u00a0al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J\u00a0Clin Epidemiol 62:1006\u20131012","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"1132_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bja\/aer126","volume":"107","author":"Power","year":"2011","unstructured":"Power I (2011) An update on analgesics. Br J Anaesth 107:19\u201324","journal-title":"Br J Anaesth"},{"key":"1132_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-2999(98)00195-2","volume":"349","author":"Reimann","year":"1998","unstructured":"Reimann W, Schneider F (1998) Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine. Eur J Pharmacol 349:199\u2013203","journal-title":"Eur J Pharmacol"},{"key":"1132_CR23","doi-asserted-by":"crossref","unstructured":"Shapiro DY, Etropolski MS, Lange B et\u00a0al (2010) Tapentadol prolonged release for painful diabetic peripheral neuropathy: efficacy and safety by prior opioid experience and dose category. In: NeuPSIG. Athens, Greece","DOI":"10.1016\/S1754-3207(10)70297-2"},{"key":"1132_CR24","doi-asserted-by":"crossref","unstructured":"Shapiro DY, Lange R, Okamoto A et al. (2010) Patient global impression of change associated with tapentadol prolonged release for the management of painful diabetic peripheral neuropathy. In: NeuPSIG, Athen, Griechenland","DOI":"10.1016\/S1754-3207(10)70507-1"},{"key":"1132_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O et\u00a0al (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17:93\u2013101","journal-title":"Pharmacogenet Genomics"},{"key":"1132_CR26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1213\/ane.0b013e31817b796e","volume":"107","author":"Stamer","year":"2008","unstructured":"Stamer UM, Stuber F, Muders T et\u00a0al (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107:926\u2013929","journal-title":"Anesth Analg"},{"key":"1132_CR27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1034\/j.1399-6576.2001.450102.x","volume":"45","author":"Tramer","year":"2001","unstructured":"Tramer MR (2001) A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part\u00a0I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand 45:4\u201313","journal-title":"Acta Anaesthesiol Scand"},{"key":"1132_CR28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1034\/j.1399-6576.2001.450103.x","volume":"45","author":"Tramer","year":"2001","unstructured":"Tramer MR (2001) A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anaesthesiol Scand 45:14\u201319","journal-title":"Acta Anaesthesiol Scand"},{"key":"1132_CR29","doi-asserted-by":"crossref","unstructured":"Tzschentke TM, Christoph T, Kogel B et\u00a0al (2007) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J\u00a0Pharmacol Exp Ther 323:265\u2013276","DOI":"10.1124\/jpet.107.126052"},{"key":"1132_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00482-010-1004-1","volume":"25","author":"Tzschentke","year":"2011","unstructured":"Tzschentke TM, Christoph T, Schroder W et\u00a0al (2011) Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview. Schmerz 25:19\u201325","journal-title":"Schmerz"},{"key":"1132_CR31","doi-asserted-by":"crossref","unstructured":"Vorsanger G, Xiang J, Okamoto A et\u00a0al (2010) Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J\u00a0Opioid Manag 6:169\u2013179","DOI":"10.5055\/jom.2010.0015"},{"key":"1132_CR32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","volume":"10","author":"Wild","year":"2010","unstructured":"Wild JE, Grond S, Kuperwasser B et\u00a0al (2010) Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 10:416\u2013427","journal-title":"Pain Pract"},{"key":"1132_CR33","doi-asserted-by":"crossref","unstructured":"Zhao SZ, Chung F, Hanna DB et\u00a0al (2004) Dose-response relationship between opioid use and adverse effects after ambulatory surgery. J\u00a0Pain Symptom Manage 28:35\u201346","DOI":"10.1016\/j.jpainsymman.2003.11.001"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-011-1132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-011-1132-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-011-1132-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T22:08:15Z","timestamp":1640902095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-011-1132-2"}},"subtitle":["Eine Metaanalyse randomisierter, kontrollierter Vergleichsstudien","A meta-analysis of randomized controlled comparative studies"],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s00482-011-1132-2","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}